Cargando…

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study

BACKGROUND: Schizophrenia is a severe psychiatric disorder. Poor medical adherence increases relapse rate. Long-acting injection of antipsychotic agent is developed for improving medical adherence. In this study, we examined the effect of paliperidone long-acting injection (PLAI) treatment in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Hsue-Wei, Huang, Chin-Yu, Yen, Yung-Chieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518212/ https://www.ncbi.nlm.nih.gov/pubmed/34654391 http://dx.doi.org/10.1186/s12888-021-03513-7

Ejemplares similares

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION
por: Kim, Seoyoung, et al.
Publicado: (2020)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

PM411. Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
por: Brown, Brianne, et al.
Publicado: (2016)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
por: Debaveye, Sam, et al.
Publicado: (2019)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation
por: Helland, Arne, et al.
Publicado: (2017)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
por: Chue, Pierre, et al.
Publicado: (2016)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)
por: Segarra, R, et al.
Publicado: (2021)

Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
por: Gutiérrez‐Rojas, Luis, et al.
Publicado: (2022)

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data)
por: Mauri, Massimo Carlo, et al.
Publicado: (2022)

Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report
por: Wang, Feng, et al.
Publicado: (2023)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018)

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
por: Liu, Jie, et al.
Publicado: (2022)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
por: González-Rodríguez, Alexandre, et al.
Publicado: (2015)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS?
por: Zipursky, Robert, et al.
Publicado: (2018)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada, Ryohei, et al.
Publicado: (2018)

M197. SEASONAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: OUTCOMES IN NATURALISTIC SETTINGS (SEASONS STUDY) OBSERVATIONAL RETROSPECTIVE MULTICENTRE CANADIAN STUDY ON 3MONTH-FORMULATION OF LONG-ACTING INJECTABLE PALIPERIDONE PALMITATE
por: Corbeil, Olivier, et al.
Publicado: (2020)

S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON
Publicado: (2020)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
por: Markovic, M.
Publicado: (2022)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo, Rosaria, et al.
Publicado: (2019)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Desai, Mitesh, et al.
Publicado: (2018)

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report
por: Cicek, Erdinc, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8suoqs268bhdnvr2ei37is3l31